FDA Approves First in Class FcRn Blocker IMAAVY (Nipocalimab aahu) for Warm Autoimmune Hemolytic Anemia

1 day ago

5 min read

On August 24, 2026, the U.S. Food and Drug Administration approved Janssen Biotech’s IMAAVY (nipocalimab-aahu) injection for adult and pediatric patients aged 12 years and older currently or previously treated with corticosteroids (1,2). This landmark decision represents the first therapy proven safe and effective specifically for warm autoimmune hemolytic anaemia (wAIHA). As a first-in-class treatment, IMAAVY offers clinical management for an underserved community that has historically lacked disease-specific options (2). In this report, we review the pathophysiology of wAIHA, the regulatory profile of IMAAVY, key efficacy data from the pivotal ENERGY study, and essential safety guidelines for healthcare professionals (1,2).

Pathophysiology, Epidemiology, and Clinical Burden of Autoantibody Mediated Hemolysis

Warm autoimmune hemolytic anaemia is a rare, life-threatening blood disorder characterized by the pathogenic, IgG-mediated destruction of red blood cells at normal body temperature. Immunoglobulin G (IgG) autoantibodies mistakenly tag red blood cells, marking them for premature splenic clearance and phagocytosis by immune cells. This accelerated destruction outpaces the bone marrow's regenerative capacity, leading to a severe deficiency in mature red blood cells, profound anaemia, and debilitating fatigue. Affecting approximately 1 to 3 individuals per 100,000 annually, wAIHA is the most common form of autoimmune hemolytic anaemia, with about 1 in 8,000 individuals living with the disease (1,2). Disease incidence increases in individuals over 50 years of age, and patients suffer a significantly elevated risk of serious systemic complications, including venous thromboembolism, acute renal failure, and infections (2).

Limitations of Non-Specific Immunosuppression and Corticosteroids

Historically, the management of wAIHA has faced massive therapeutic limitations due to a lack of disease-specific options. Treatment has conventionally relied on corticosteroids and broad-spectrum immunosuppressants. While these non-specific interventions can temporarily reduce red blood cell destruction, they suppress the entire immune system rather than selectively targeting the IgG autoantibodies driving the disease. This broad immunosuppression leaves patients trapped in cycles of remission and disease relapse, while exposing them to serious clinical complications like chronic infections. Consequently, there is an urgent unmet medical need for targeted therapies that selectively reduce pathogenic autoantibodies without compromising overall immunity (2).

Drug Profile and FDA Approval of IMAAVY

IMAAVY (nipocalimab-aahu) is an immunoselective neonatal Fc receptor (FcRn) blocker designed to bind with high affinity to FcRn. This mechanism blocks FcRn-mediated recycling of IgG, thereby accelerating the clearance of circulating pathogenic IgG autoantibodies while preserving B-cell function (2). To expedite development, the FDA granted IMAAVY® Fast Track, Priority Review, and Orphan Drug designations for wAIHA. Efficacy and safety were rigorously evaluated in the Phase 2/3 ENERGY study, a 24-week, randomized, double-blind, placebo-controlled clinical trial. The trial randomized 115 to 118 patients with a confirmed wAIHA diagnosis of at least 3 months, low haemoglobin (below 10 g/dL), active hemolysis, and a positive direct antiglobulin test. Patients were randomized to receive placebo, the approved IMAAVY® dose of 30 mg/kg intravenously every 4 weeks, or an alternative dose of 15 mg/kg every 2 weeks, with stable background wAIHA therapies permitted (1,2).

Clinical Evidence – The ENERGY TRIAL

The ENERGY trial was a pivotal Phase 3 study designed to evaluate the efficacy and safety of IMAAVY (nipocalimab aahu) in patients with warm autoimmune hemolytic anemia (wAIHA). The trial specifically assessed whether FcRn blockade could deliver durable hematologic responses and meaningful improvements in patient reported outcomes, addressing a critical unmet need in this rare condition (2,3).

The primary efficacy endpoint in the ENERGY trial was durable hemoglobin response, defined as maintaining a hemoglobin concentration of ≥10 g/dL and an increase from baseline of ≥2 g/dL for at least 28 consecutive days starting by Week 16, without rescue therapies (2,3).

Durable Response Rates

Around 24% of patients in the approved IMAAVY 30 mg/kg group achieved a durable response compared to 8% in the placebo arm (1,2). In contrast, the 15 mg/kg every 2 weeks regimen did not demonstrate superiority over placebo (1-3).

Therapeutic Onset

IMAAVY treated patients showed rapid onset, with a mean hemoglobin increase of 1 g/dL by Week 1 (2). Among responders in the 30 mg/kg group, the median time to first hemoglobin response was 4.1 weeks versus 12.1 weeks for placebo (1-3).

Patient Reported Outcomes

At Week 24, IMAAVY treated patients achieved a 3.5 point greater mean change in FACIT Fatigue score compared to placebo, reflecting clinically meaningful fatigue relief (1-3).

Special notes for the clinician

The safety profile of IMAAVY in wAIHA is consistent with its established database in generalized myasthenia gravis, approved in April 2025. The most common adverse reactions reported in 10% or more of wAIHA patients treated with IMAAVY were peripheral oedema, diarrhoea, and pyrexia. Infusion-related reactions occurred in some patients, presenting as headache, fatigue, influenza-like illness, rash, nausea, dizziness, chills, or skin erythema. Because IMAAVY blocks FcRn and lowers IgG levels, it can increase the risk of serious infections; therefore, clinicians should delay infusions in patients with active infections. Patients must be counselled to immediately report symptoms of infection, such as fever, chills, cough, sore throat, trouble breathing, or burning when urinating. Severe hypersensitivity reactions, including angioedema and anaphylaxis, are possible, and the drug is contraindicated in patients with a history of severe allergic reaction to nipocalimab-aahu (2).

Paradigm-Shifting Advancement in wAIHA Treatment

The FDA approval of IMAAVY represents a paradigm-shifting advancement in wAIHA therapy. By selectively blocking FcRn, IMAAVY reduces circulating pathogenic IgG autoantibodies while preserving essential B-cell function. This first-in-class approval provides haematologists with an effective, targeted tool to achieve durable haemoglobin stabilisation and fatigue relief. Ultimately, IMAAV® successfully transitions wAIHA management from broad immunosuppression to an era of targeted immunobiology (2).

About the Author

Dr. Manisha Dadlani is a Dental Surgeon and Medical Writer with 5+ years of clinical experience and formal training in medical writing. She combines clinical expertise with analytical thinking to develop evidence-based, insight-driven content that supports effective scientific communication across the healthcare and life sciences landscape.

References:

FDA Approves First Drug for Warm Autoimmune Hemolytic Anemia. Available at: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-warm-autoimmune-hemolytic-anemia Accessed on 15 September, 2026.
FDA approves IMAAVY (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anaemia (wAIHA), representing a landmark advancement for patients. Available at: https://www.jnj.com/media-center/press-releases/fda-approves-imaavy-nipocalimab-aahu-as-first-ever-treatment-for-warm-autoimmune-hemolytic-anemia-waiha-representing-a-landmark-advancement-for-patients Accessed on 15 September, 2026.
Fattizzo B et al. Nipocalimab for warm autoimmune hemolytic anemia: results from the Phase 2/3 randomized, double-blind ENERGY study, Presented at EHA 2026 Congress, Available at https://library.ehaweb.org/eha/2026/eha-2026/4206854/bruno.fattizzo.nipocalimab.for.warm.autoimmune.hemolytic.anemia.results.from.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DS300 Accessed on 15 September, 2026.

Disclaimer

The content published on this platform has been developed by independent medical writers from diverse healthcare backgrounds, including members of the MedWriters Alumni Network. While every effort has been made to ensure accuracy, the authors, Rxnews team, partners, agents, and sponsors accept no responsibility for errors, omissions, or inaccuracies in this article, whether due to negligence or otherwise, nor for any consequences arising from its use. Inclusion or exclusion of any product does not imply endorsement or rejection by the publisher. For complaints or feedback, please write to contact@rxnews.in